Good afternoon,
With only a couple months until D day, I've been quietly catching myself up on where the last 2 years has gone with Botanix.
I noticed on acquisition of Sofdra, Bot was liable for royalties up to 20%. It looks like they bought out the royalties in 2022 from the intermediary, leaving only a 5% royalty payable on new sales to the laboratory.
First - is this correct and is this the only royalty they are now liable for?
Second, I noted mentioning of ballpark pricing based on currently re-imbursed products. The quoted reimbursement was $680USD per month and that BOT were aware of the limit most payers were willing to reimburse, and that the price should be a premium above other products because of the better safety and efficacy.... so somewhere north of $680.
In Japan this same product is selling for about $70USD depending on the exchange rate at the time ( It was closer to 90 USD before that ), but I am not aware for the JDM pharma, do they recieve additional assistance in the manufacturing, or is $70 USD for them able to completely cover the cost of manufacture to sales, royalties, with profits included?
If that is the case, then I would see no reason BOT are not able to have similar costs from manufacture to product sales of under $70, which then points towards quite massive product margins.
Take $680 per unit, minus 5% royalty, minus $70 cost leaves $576USD profit per unit.
12 units per year - $6,912 per year per patient profit
With equivalent patient numbers Kaken manged in year 2023 ( around 15,000 )
103 million USD profit, on less than 1 % market penetration.
With a PE of 20, that would equate to about 9.3 times the current share price, or $2 Aud per share
Every 1% market penetration in the USA is 254 million USD.
Botanix stated US marked includes 3.7 million people who are seeking treatment.
If we assume 1% market penetration , 254 million USD is 389 million AUD.
20:1 PE is 7.78 Billion Aud = share price 23x today, or $ 4.95
I notice some analysts used a 5% market penetration over an 8 year period.
5% = 5 x 389 AUD in profit = 1.945 Billion AUD
PE 20:1 gives 38.9 Billion AUD, and SP 115 x today, or $24.7 AUD Share price
Does this sound about right?
Blaze away.....
- Forums
- ASX - By Stock
- BOT
- Sofdra - Post approval royalties, costs and earnings
Sofdra - Post approval royalties, costs and earnings
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
0.050(14.3%) |
Mkt cap ! $724.0M |
Open | High | Low | Value | Volume |
35.5¢ | 40.0¢ | 35.5¢ | $6.075M | 15.87M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 287187 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 1920397 | 33 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 0.385 |
7 | 681262 | 0.380 |
1 | 450000 | 0.375 |
5 | 213742 | 0.370 |
4 | 343289 | 0.365 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 1772160 | 29 |
0.405 | 176676 | 4 |
0.410 | 108685 | 9 |
0.415 | 100000 | 1 |
0.420 | 1135453 | 6 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online